

Lian Liu, MD

CEO
PacGenomics

Before PacGenomics, Dr. Liu was a co-founder and CEO of PGD Science, Inc., a well-known FISH-based PGS company based in Southern California, which is now partnered with PacGenomics. Dr. Liu has in-depth genomics knowledge and extensive hands-on experience in embryo biopsy and PGS for IVF. Dr. Liu received his M.D. degree from Tongji Medical University in China and practiced neurosurgery prior to co-founding PGD Science, Inc. He leads the PacGenomics team with his innovative spirit and desire to improve the status quo of health care services through single-cell technologies.

Curriculum Vitae:

Lian Liu, M.D.

Contact information: Email: lliu@pacgenomics.com

Phone: 310-927-0643
Fax: 818-936 0511

Current Position:

Owner and President, PacGenomics Canada, INC
Owner and CEO, New-Generation Genomics, INC
Owner and CEO, PGD Science, INC
Owner and CEO, Pacgenomics, INC

EDUCATION AND TRAINING:

Post-doc researcher : University of Florida, Gainesville
Department of Neurosurgery
Gainesville, Florida 32610
10/1999 to 12/2001

Residence Department of Neurosurgery
Red Cross Hospital of Guangzhou,
Guangzhou, China 1989-1999

Medical School: Tongji Medical University
Wuhan, China 1984-1989

CERTIFICATION:

- Passed USMLE medical board examination step1/step2
- Qualified attending Neurosurgeon in China

PROFESSIONAL EXPERIENCE:

07/1989----08/1999:

Neurosurgeon Department of Neurosurgery
 Red Cross Hospital of Guangzhou,
 Guangzhou, China 1989-1999

02/2002----Present:

CEO & Owner PGD Science INC, 28222 Agoura RD, Suite 200, Agoura Hills, CA 91301

02/2011----Present:

CEO & Owner PacGenomics, 28222 Agoura RD, Suite 200, Agoura Hills, CA 91301

08/2014---Present:

CEO & Owner New-generation Genomics, INC

Current:

CEO & Owner PacGenomics Canada, 135 Queens Plate Drive, suite 600, Toronto, M9W 6V7

MEMBERSHIPS, PROFESSIONAL SOCIETIES:

- Chinese Medical Society of Neurosurgeons, Member, 1989--present.
- Member of American Society for Reproductive Medicine (ASRM). 2014-present

Other:

- In-house developed array-based PGS platform, first Roche Nimblegen-based array PGS
- in-house developed array-based PGS platform, first Agilent-based array PGS in US. First 8-hr TAT PGS protocol
- In-house developed first 8-hr TAT high resolution NGS-based PGS system (Validation pending, expected to finish within a month)
- CEO of a CTC project, leading an ongoing clinical validations of CTC in New-generation Genomics, INC
- Invited speaker in ACMG Utah as Agilent customer, on cell-based NIPT

Publications:...